FDA Approves Second Gene Therapy for Hemophilia B FDA Approves Second Gene Therapy for Hemophilia B
Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Internal Medicine News Alert Source Type: news
More News: Bleeding | Gene Therapy | Genetics | Haemophilia | Health | Hemophilia | Internal Medicine | Pfizer